Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 6, 1999, Pages 1025-1030

  Terrien, Maria Helena ^a   Rahm, François ^a   Fellrath, Jean Marc ^a   Spertini, François ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Acoustic rhinometry; Allergen challenge; Allergic rhinitis; Antihistamine; Fexofenadine; Nasal provocation test; Terfenadine

Indexed keywords

FEXOFENADINE; TERFENADINE;

ADULT; ALLERGIC RHINITIS; ALLERGY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; MALE; NOSE AIRFLOW; NOSE CONGESTION; NOSE PROVOCATION TEST; NOSE SECRETION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RHINOMETRY; RHINORRHEA; SEASONAL VARIATION; SNEEZING;

EID: 0032784402     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70174-0     Document Type: Article

References (27)

1. 1. McTavish D, Goa KL, Ferrill M. Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy. Drugs 1990;39:552-74.
2. 2. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
3. 3. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996;36:233-52.
4. 4. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996;131:472-80.
5. 5. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantinela LR. Terfenadine-ketoconazole interaction. JAMA 1993;269:1513-8.
6. 6. Zenich AD, Haxby DC. Drug interactions associated with terfenadine and related nonsedating antihistamines. West J Med 1996;164:68-9.
7. 7. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996;275:1339-41.
8. 8. Vermeeren A, O'Hanlon JF. Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 1998;101:306-11.
9. 9. Lippert C, Ling J, Brown P, et al. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers [abstract]. Pharm Res 1995;12(suppl):S390.
10. 10. Simons FER, Simons KJ. Peripheral H1 -blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997;79:530-2.
11. 11. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8.
12. 12. Stern M, Bloom M. Fexofenadine HC1 versus cetirizine as a once daily treatment for seasonal allergic rhinitis. In: British Society for Allergy and Clinical Immunology Book of Abstracts. 1996. p. 10.
13. 13. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997;79:533-40.
14. 14. Tinkelman D, Falliers C, Bronsky E, Kaiser H, Mason J. Efficacy and safety of fexofenadine HC1 in fall seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1996;97:435.
15. 15. Pratt C, Mason J, Russell T, Ahlbrandt R. Effect of fexofenadine HC1 on corrected QT interval (QTc). Allergy 1997;52 (suppl 37):67.
16. 16. Zweiman B, Getsy J, Kalenian M, et al. Nasal airway changes assessed by acoustic rhinometry and mediator release during immediate and late reactions to allergen challenge. J Allergy Clin Immunol 1997;100:624-31.
17. 17. Youlten LJ. Nasal airway patency measurement in the assessment of rhinitis therapy. Arbeiten aus dem Paul-Ehrlich-Institut, dem Georg-Speyer-Haus und dem Ferdinand-Blum-Institut Zu Frankfurt A.M. 1983;78:111-3.
18. 18. Druce HM. Nasal provocation challenge-strategies for experimental design. Ann Allergy 1998;60:191-6.
19. 19. Østerballe O. Nasal and skin sensitivity during specific immunotherapy with two major allergens 19, 25 and partially purified extract timothy grass pollen. Allergy 1982;37:169-74.
20. 20. Youlten LJF. Nasal airway patency measurement in the assessment of rhinitis therapy. In: Brede HD, Going H, Schaeffer M, editors. Arbeiten aus dem Paul-Ehrlich-Institut, dem Georg-Speyer-Haus und dem Ferdinand-Blum-Institut. Stuttgart: Gustav Fischer Verlag; 1983. p. 111-3.
21. 21. Kolly M, Pécoud A. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen. Br J Clin Pharmacol 1986;22:389-94.
22. 22. Mygind N, Borum P, Secher C, Kirkegaard J. Nasal challenge. Eur J Respir Dis 1986;68:31-4.
23. 23. Druce HM. Nasal provocation challenge-strategies for experimental design. Ann Allergy 1988;60:191-6.
24. 24. Druce HM, Schumacher MJ. Nasal provocation challenge. J Allergy Clin Immunol 1990;86:261-4.
25. 25. Melillo G, Bonini S, Cocco G, et al. Provocation tests with allergens. Allergy 1997;52:5-36.
26. 26. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzenmittelforschung/Drug Res 1982;32:1185-90.
27. 27. Eller MG, Walker BJ, Westmark PA, et al. Pharmacokinetics of terfenadine in healthy elderly subjects. J Clin Pharmacol 1992;32:267-71.